BSX Raises 2025 Financial Outlook: What's Backing It?
In the first quarter, the company delivered organic sales growth of 18%, exceeding the guided range of 14-16%. Adjusted EPS was $0.75, marking a 34% year-over-year increase and surpassing the forecasted $0.66-$0.68 range. This growth reflects the durability of BSX's category leadership strategy, which is powered through meaningful innovation and clinical evidence generation.
Boston Scientific's Cardiology segment sales surged 31%, driven by robust growth in products such as WATCHMAN, AGENT drug-coated balloon (DCB) and FARAPULSE. WATCHMAN gained market share through rising concomitant procedures. In addition, its Electrophysiology ('EP') business experienced robust growth, with sales up 145% year over year. This has positioned BSX as the second-largest player globally, largely due to the rapid adoption of pulsed field ablation (PFA) with FARAPULSE. Geographically, sales in the United States rose 31%, while Asia-Pacific and EMEA regions delivered 11% and 8% sales growth, respectively. Asia-Pacific growth was led by double-digit growth in Japan and high single-digit growth in China (despite volume-based procurement headwinds).
BSX also plans to successfully offset the tariff impact through full-year organic sales guidance raise, targeted discretionary spending reductions and a $0.01FX benefit.
Boston Scientific's Competitors
Edwards Lifesciences EW reiterated its 2025 sales growth forecast of 8-10% but raised the sales dollar guidance range by $100 million, reaching $5.7-$6.1 billion. The revision was made to account for the recent movement in foreign exchange rates. Edwards continues to expect 2025 adjusted EPS to be in the range of $2.40-$2.50 despite headwinds from tariffs. This growth trajectory is driven by the continued global adoption of SAPIEN 3 Ultra RESILIA, PASCAL and EVOQUE systems.
Stryker SYK raised its sales guidance for 2025, led by strong first-quarter performance, continued capital demand and robust commercial execution. The company now expects total revenues to grow in the range of 8.5-9.5% on an organic basis (previously 8-9%). However, SYK lowered its EPS guidance to $13.20-$13.45 from $13.45-$13.70, reflecting headwinds from the Inari Medical acquisition and a $200 million impact from announced tariffs.
BSX Stock Price Performance, Valuation and Estimate Trend
Shares of Boston Scientific have gained 33.4% in the past year compared with the industry's growth of 8.8%. The S&P 500 composite has grown 9.3% in the same period.
Image Source: Zacks Investment Research
From a valuation standpoint, BSX trades at a forward 12-month price-to-earnings ratio (P/E) of 33.19X, above the industry's 20.83X.
The Zacks Consensus Estimate for BSX's earnings has been on the rise over the past 60 days.
BSX stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
Stryker Corporation (SYK): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
22 minutes ago
- Globe and Mail
PRIMECAP Management Co Reduces Stake in Tesla Motors
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. PRIMECAP Management Co, managed by Theofanis Kolokotrones, recently executed a significant transaction involving Tesla Motors ((TSLA)). The hedge fund reduced its position by 165,045 shares. Spark's Take on TSLA Stock According to Spark, TipRanks' AI Analyst, TSLA is a Outperform. Tesla's overall stock score reflects strong financial health and strategic advancements in technology and energy. While technical indicators and high valuation present challenges, the company's robust earnings call and leadership retention efforts provide a positive outlook for future growth. To see Spark's full report on TSLA stock, click here. More about Tesla Motors YTD Price Performance: -10.61% Average Trading Volume: 105,651,938 Current Market Cap: $1093.5B Disclaimer & Disclosure Report an Issue
Globe and Mail
22 minutes ago
- Globe and Mail
BioSig Technologies Inc. Announces Pricing of $15 Million Public Offering
Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ('BioSig' or the 'Company'), which recently merged with Streamex Exchange Corporation ('Streamex') (NASDAQ: BSGM), today announced the pricing of its previously announced underwritten public offering of 3,852,149 shares of common stock at a public offering price of $3.90 per share. The offering is expected to close on or around August 15, 2025 subject to customary closing conditions. The gross proceeds from the offering, before deducting underwriter discounts and commissions and other estimated offering expenses are expected to be approximately $15,023,381.10. BioSig intends to use the net proceeds from the offering to purchase gold bullion in accordance with its investment policy, for working capital and for general corporate purposes. Clear Street and Needham & Company are acting as joint book-running managers of the offering. The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-276298) declared effective by the Securities and Exchange Commission (the 'SEC') on December 17, 2024. A final prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission, together with an accompanying base prospectus. The securities may be offered only by means of a written prospectus forming a part of the effective registration statement. Copies of the final prospectus supplement relating to the offering, together with the accompanying base prospectus, may be obtained, when available from the SEC's website at from Clear Street, Attention: Syndicate, 4 World Trade Center, 150 Greenwich St, Floor 46, New York, NY 10007, or by email at syndicate@ and Needham & Company, 250 Park Avenue, 10th Floor, New York, NY 10177, Attn: Prospectus Department, prospectus@ or by telephone at (800) 903-3268. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein. BioSig will not, and has been advised by the joint book-running managers that they and their affiliates will not, sell any of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Streamex Streamex is a RWA and gold tokenization company building Institutional grade infrastructure to bring the gold market on chain, enabled by a gold denominated treasury and an institutional grade tokenization platform. Streamex is a wholly owned subsidiary of BioSig Technologies, Inc. About BioSig Technologies BioSig Technologies, Inc. is a medical device technology company with an advanced digital signal processing technology platform, the PURE EP™ Platform that delivers insights to electrophysiologists for ablation treatments of cardiovascular arrhythmias. The PURE EP™ Platform enables electrophysiologists to acquire raw signal data in real-time—absent of unnecessary noise or interference—to maximize procedural success and minimize unnecessary inefficiencies. As physician advocates, we believe that the ability to maintain the integrity of intracardiac signals with precision and clarity without driving up procedural costs has never been more pertinent. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond our control. It is possible that our actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether we will be able to realize the benefits of the acquisition of Streamex, whether shareholder approval of the acquisition and recently announced convertible debenture financing and standby equity purchase agreement will be obtained, and whether we will be able to maintain compliance with Nasdaq's listing criteria in connection with the acquisition and otherwise. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in forward-looking statements, see our filings with the Securities and Exchange Commission, including the section titled "Risk Factors" in our Annual Report on Form 10-K, filed with the SEC on April 15, 2025. We assume no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law.
Globe and Mail
22 minutes ago
- Globe and Mail
TPI Composites, Inc. Advances Chapter 11 Process with Court Approval of First-Day Motions
Secures Access to Liquidity and Financial Flexibility Operations Continue Uninterrupted for Employees, Customers, and Supply Partners Company Focused on Executing Strategic Initiatives for Long-Term Stability SCOTTSDALE, Ariz., Aug. 13, 2025 (GLOBE NEWSWIRE) -- TPI Composites, Inc. (NASDAQ: TPIC) together with its domestic subsidiaries (collectively, 'TPI' or the 'Company') announced today that the U.S. Bankruptcy Court for the Southern District of Texas (the 'Bankruptcy Court') approved all first-day motions filed by the Company in connection with its voluntary chapter 11 proceedings. The approvals provide the Company with the operational flexibility and liquidity necessary to continue normal business operations during the chapter 11 process. Key motions approved include, interim approval for debtor-in-possession financing from its senior secured lenders of up to $82.5 million, the continuation of employee wages and benefits, maintenance of cash management systems, and the authority to pay certain prepetition obligations critical to ongoing operations. 'Our priority is to maintain stability and support for our employees, customers, and partners during this process,' said Bill Siwek, Chief Executive Officer of TPI. 'The court's approval of these first-day motions allows us to focus on executing our strategic initiatives to strengthen the Company for the long term.' Additional Information Additional information regarding the Company's court-supervised process is available at Court filings and other information related to the proceedings are available on a separate website administrated by the Company's claims agent, Kroll, at by calling Kroll representatives at (877) 280-2696 within the U.S. & Canada (or +1 (646) 290-7082 internationally for calls originating outside of the U.S.); or by sending an email to TPIinfo@ About TPI TPI Composites, Inc. is a global company focused on innovative and sustainable solutions to decarbonize and electrify the world. TPI delivers high-quality, costeffective composite solutions through long-term relationships with leading OEMs in the wind markets. TPI is headquartered in Scottsdale, Arizona and operates factories in the U.S., Mexico, Türkiye and India. TPI operates additional engineering development centers in Denmark and Germany and global service training centers in the U.S. and Spain. Forward-Looking Statements This release contains forward-looking statements made pursuant to safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward looking statements include statements, among other things, concerning: the adoption, implementation and consummation of a Chapter 11 plan of reorganization; the commencement of Chapter 11 proceedings in U.S. bankruptcy court; growth of the wind energy and electric vehicle markets and our addressable markets for our products and services; effects on our financial statements and our financial outlook; our business strategy, including anticipated trends and developments in and management plans for our business and the wind industry and other markets in which we operate; future financial results, operating results, revenues, gross margin, operating expenses, profitability, products, projected costs, warranties, our ability to improve our operating margins, and capital expenditures. These forward-looking statements are often characterized by the use of words such as 'estimate,' 'expect,' 'anticipate,' 'potential,' 'project,' 'plan,' 'intend,' 'seek,' 'believe,' 'forecast,' 'foresee,' 'likely,' 'may,' 'should,' 'goal,' 'target,' 'might,' 'will,' 'could,' 'predict,' 'continue' and the negative or plural of these words and other comparable terminology. Forward-looking statements are only predictions based on our current expectations and our projections about future events. You should not place undue reliance on these forward-looking statements. We undertake no obligation to update any of these forward-looking statements for any reason. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by these statements. These factors include, but are not limited to, the matters discussed in 'Risk Factors,' in our Annual Report on Form 10-K and other subsequent filings with the SEC.
